NCT06703710

To Evaluate the Safety/Tolerability and Pharmacokinetic Characteristics in Healthy Volunteers

A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose, Phase 1 Clinical Trial to Evaluate the Safety/Tolerability and PK Characteristics, and to Explore Food Effect and Ethnic Difference of JW2286 in Healthy Volunteers

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 72 (estimated)
• Sponsor: JW Pharmaceutical · Industry
• Sex: All
• Age: 19 Years – 50 Years
• Healthy volunteers: Accepted

Summary

This clinical trial is a randomized, double-blind, placebo-controlled, single ascending dose, phase 1 clinical trial to evaluate the safety/tolerability and pharmacokinetic characteristics, and to explore food effect and ethnic difference of JW2286 after oral administration in healthy adults.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	JW2286	a single administration of JW2286 per dose
DRUG	Placebo of JW2286	a single administration of Placebo of JW2286 per dose

Timeline

• Start date: 2025-01-06
• Primary completion: 2025-11-01
• Completion: 2026-01-01
• First posted: 2024-11-25
• Last updated: 2025-01-13

Locations

1 site across 1 country: South Korea